132 related articles for article (PubMed ID: 31099568)
1. Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
Bechmann N; Kniess T; Pietzsch J
J Med Chem; 2019 Jul; 62(14):6525-6539. PubMed ID: 31099568
[TBL] [Abstract][Full Text] [Related]
2. Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer.
Makar S; Saha T; Swetha R; Gutti G; Kumar A; Singh SK
Bioorg Chem; 2020 Jan; 94():103380. PubMed ID: 31757413
[TBL] [Abstract][Full Text] [Related]
3. An NO donor approach to neuroprotective and procognitive estrogen therapy overcomes loss of NO synthase function and potentially thrombotic risk.
VandeVrede L; Abdelhamid R; Qin Z; Choi J; Piyankarage S; Luo J; Larson J; Bennett BM; Thatcher GR
PLoS One; 2013; 8(8):e70740. PubMed ID: 23976955
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Potential of Nitric Oxide‒Releasing Selective Estrogen Receptor Modulators in Malignant Melanoma.
Bechmann N; Calsina B; Richter S; Pietzsch J
J Invest Dermatol; 2022 Aug; 142(8):2217-2227. PubMed ID: 34990694
[TBL] [Abstract][Full Text] [Related]
5. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
6. Selectively targeting estrogen receptors for cancer treatment.
Shanle EK; Xu W
Adv Drug Deliv Rev; 2010 Oct; 62(13):1265-76. PubMed ID: 20708050
[TBL] [Abstract][Full Text] [Related]
7. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer.
Katzenellenbogen BS; Katzenellenbogen JA
Breast Cancer Res; 2000; 2(5):335-44. PubMed ID: 11250726
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor.
Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z
J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419
[TBL] [Abstract][Full Text] [Related]
10. Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
O'Boyle NM; Barrett I; Greene LM; Carr M; Fayne D; Twamley B; Knox AJS; Keely NO; Zisterer DM; Meegan MJ
J Med Chem; 2018 Jan; 61(2):514-534. PubMed ID: 28426931
[TBL] [Abstract][Full Text] [Related]
11. Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives.
Smith HM; Knox AJ; Zisterer DM; Lloyd DG; Meegan MJ
Med Chem; 2007 Mar; 3(2):135-55. PubMed ID: 17348852
[TBL] [Abstract][Full Text] [Related]
12. Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
Qin Z; Kastrati I; Chandrasena RE; Liu H; Yao P; Petukhov PA; Bolton JL; Thatcher GR
J Med Chem; 2007 May; 50(11):2682-92. PubMed ID: 17489582
[TBL] [Abstract][Full Text] [Related]
13. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
Power KA; Thompson LU
Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.
Shen J; Tan C; Zhang Y; Li X; Li W; Huang J; Shen X; Tang Y
J Med Chem; 2010 Jul; 53(14):5361-5. PubMed ID: 20553023
[TBL] [Abstract][Full Text] [Related]
15. Binding capacity of ER-α ligands and SERMs: comparison of the human, dog and cat.
Toniti W; Suthiyotha N; Puchadapirom P; Jenwitheesuk E
Asian Pac J Cancer Prev; 2011; 12(11):2875-9. PubMed ID: 22393957
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.
Kelly PM; Bright SA; Fayne D; Pollock JK; Zisterer DM; Williams DC; Meegan MJ
Bioorg Med Chem; 2016 Sep; 24(18):4075-4099. PubMed ID: 27407030
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test.
Clark JA; Alves S; Gundlah C; Rocha B; Birzin ET; Cai SJ; Flick R; Hayes E; Ho K; Warrier S; Pai L; Yudkovitz J; Fleischer R; Colwell L; Li S; Wilkinson H; Schaeffer J; Wilkening R; Mattingly E; Hammond M; Rohrer SP
Neuropharmacology; 2012 Nov; 63(6):1051-63. PubMed ID: 22796107
[TBL] [Abstract][Full Text] [Related]
18. Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.
Chan KK; Leung TH; Chan DW; Wei N; Lau GT; Liu SS; Siu MK; Ngan HY
J Endocrinol; 2014 May; 221(2):325-36. PubMed ID: 24819599
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.
Paterni I; Granchi C; Katzenellenbogen JA; Minutolo F
Steroids; 2014 Nov; 90():13-29. PubMed ID: 24971815
[TBL] [Abstract][Full Text] [Related]
20. New scaffolds for the design of selective estrogen receptor modulators.
Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
